 |
42 Diseases |  |
0 Trials |
|
0 Trials |  |
16 News |  |
- | Varubi (rolapitant oral) / TerSera Therap, GSK, Rezonic (casopitant) / GSK
Journal: Homology modeling, virtual screening, molecular docking, and ADME approaches to identify a potent agent targeting NK2R protein. (Pubmed Central) - Oct 31, 2023
The evaluation of the in silico ADME profile, solubility, and permeability of the ligand molecules has revealed that the small molecules are potentially nontoxic and have the chance of exhibiting biological activity after oral administration. Further experimental studies (in vitro and in vivo assays) are required to evaluate the effectiveness of these inhibitors as therapeutic targets.
- ||| Clinical, P2 data, P3 data, Review, Journal: Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry. (Pubmed Central) - Jul 10, 2022
Further experimental studies (in vitro and in vivo assays) are required to evaluate the effectiveness of these inhibitors as therapeutic targets. These new compounds with novel mechanisms of action are expected to provide a greater variety of treatment options for depression if preliminary positive results are confirmed.
- || Varubi (rolapitant oral) / TerSera Therap, GSK
Retrospective data, Review, Journal: Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. (Pubmed Central) - Dec 16, 2021
For people receiving HEC, synthesised evidence does not suggest one superior treatment for prevention and control of chemotherapy-induced nausea and vomiting. For people receiving MEC, synthesised evidence does not suggest superiority for treatments including both NK₁ and 5-HT₃ inhibitors when compared to treatments including 5-HT₃ inhibitors only. Rather, the results of our NMA suggest that the choice of 5-HT₃ inhibitor may have an impact on treatment efficacy in preventing CINV. When interpreting the results of this systematic review, it is important for the reader to understand that NMAs are no substitute for direct head-to-head comparisons, and that results of our NMA do not necessarily rule out differences that could be clinically relevant for some individuals.
- || Varubi (rolapitant oral) / TerSera Therap, GSK
Retrospective data, Review, Journal: Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. (Pubmed Central) - Nov 18, 2020
No further efficacy studies are needed as there is evidence of moderate to high certainty for seven single drugs with relevant benefit for prevention of vomiting. However, additional studies are needed to investigate potential side effects of these drugs and to examine higher-risk patient populations (e.g. individuals with diabetes and heart disease).
- | Varubi (rolapitant oral) / TerSera Therap, GSK, olanzapine / Generic Mfg., netupitant (Ro 67-3189) / Helsinn, Otsuka
Retrospective data, Journal, CINV: Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. (Pubmed Central) - Sep 22, 2019
Olanzapine-based triplet was outstanding in terms of nausea control and drug price. For cancer patients with HEC, especially those suffering from delayed-phase nausea, olanzapine-based triple regimens should be an optional antiemetic choice.
- Rezonic (casopitant) / GSK
Enrollment change: Cyclophosphamide Drug Interaction Study In Cancer Patients (clinicaltrials.gov) - Nov 18, 2017
P1, N=25, Terminated, Sponsor: GlaxoSmithKline
For cancer patients with HEC, especially those suffering from delayed-phase nausea, olanzapine-based triple regimens should be an optional antiemetic choice. N=10 --> 25
- || Rezonic (casopitant) / GSK
Enrollment change: A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers (clinicaltrials.gov) - Aug 9, 2017
P1, N=97, Completed, Sponsor: GlaxoSmithKline
N=10 --> 25 N=72 --> 97
- Rezonic (casopitant) / GSK
Phase classification: An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 Days In Patients With Functional Dyspepsia (clinicaltrials.gov) - Feb 7, 2017
P2, N=13, Completed, Sponsor: GlaxoSmithKline
N=72 --> 97 Phase classification: P1 --> P2
- |||| Rezonic (casopitant) / GSK
Trial completion: A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting (clinicaltrials.gov) - Jan 22, 2017
P2, N=701, Completed, Sponsor: GlaxoSmithKline
Phase classification: P1 --> P2 No longer recruiting --> Completed
- Rezonic (casopitant) / GSK
Enrollment change, Combination therapy: A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Apr 17, 2015
P3, N=0, Withdrawn, Sponsor: GlaxoSmithKline
No longer recruiting --> Completed N=436 --> 0
- Rezonic (casopitant) / GSK
Enrollment change: Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients (clinicaltrials.gov) - Apr 17, 2015
P2, N=1, Terminated, Sponsor: GlaxoSmithKline
N=436 --> 0 N=40 --> 1
- Rezonic (casopitant) / GSK
Phase classification: GW679769 In Fibromyalgia (clinicaltrials.gov) - Apr 16, 2015
P=N/A, N=8, Completed, Sponsor: GlaxoSmithKline
N=40 --> 1 Phase classification: P2 --> P=N/A
- |||| Rezonic (casopitant) / GSK
Trial completion, Combination therapy: Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy (clinicaltrials.gov) - Apr 14, 2015
P2, N=722, Completed, Sponsor: GlaxoSmithKline
Phase classification: P2 --> P=N/A No longer recruiting --> Completed
- |||| Rezonic (casopitant) / GSK
Trial completion: Study Of GW679769 In Major Depressive Disorder (clinicaltrials.gov) - Apr 14, 2015
P2, N=356, Completed, Sponsor: GlaxoSmithKline
No longer recruiting --> Completed No longer recruiting --> Completed